Welcome to our dedicated page for Trinity Capital news (Ticker: TRIN), a resource for investors and traders seeking the latest updates and insights on Trinity Capital stock.
Trinity Capital Inc. reports developments as an alternative asset manager and specialty lender focused on private credit for growth-oriented companies. Its recurring news includes quarterly financial results, net investment income, NAV movement, new commitments, funded investments, repayments, exits, and portfolio activity across Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences.
Company updates also cover secured loans, equipment financings, warrant and equity investments, sponsored investment funds, SBIC-related activity, and growth-capital facilities for portfolio companies in technology, life sciences, medical technology, energy infrastructure, and other innovation-driven markets.
Trinity Capital (Nasdaq: TRIN) committed $30 million in growth capital to Iantrek to accelerate commercial expansion and advance its bio-interventional ophthalmic surgery product pipeline.
The debt facility will fund commercialization of AlloFlo Uveo, regulatory and development activities, scaling manufacturing and distribution, and market access efforts to broaden physician adoption.
Trinity Capital (Nasdaq: TRIN) committed $50 million in growth capital to Cala Health to support commercial expansion of its wearable tremor therapy.
Cala Health commercializes the Cala kIQ System, an FDA-cleared wrist-worn device delivering individualized noninvasive nerve stimulation for essential tremor and Parkinson's disease, prescribed for at-home use to help patients perform daily activities.
Trinity Capital (Nasdaq: TRIN) reported first quarter 2026 portfolio activity: $306 million funded and $395 million of new commitments.
Funding comprised $236M secured loans, $54M equipment financings and $16M warrant/equity investments; commitments included $304M secured loans and $75M equipment financings. Repayments and exits totaled ~$238M. Full 2026 results due May 6, 2026.
Trinity Capital (Nasdaq: TRIN) will release first quarter 2026 financial results on May 6, 2026 at 8:00 a.m. ET and host a conference call the same day at 12:00 p.m. ET. A taped replay is available until May 13, 2026; a webcast replay will remain on the company website for 90 days.
The company provided dial‑in numbers, a conference ID (TRINQ126), and a webcast link via its investor relations site for live and replay access.
Trinity Capital (Nasdaq: TRIN) committed $50 million in a debt term loan to Sage Health on March 27, 2026 to support expansion of senior-focused primary care and wellness centers in medically underserved areas. The financing brings Sage's total capital raised to $170 million.
Sage limits physicians to 500 patients each, operates in primary-care shortage neighborhoods, and integrates primary care, wellness, and care coordination to manage chronic conditions. Armentum Partners served as Sage's debt capital advisor.
Trinity Capital (Nasdaq: TRIN) declared a monthly regular dividend of $0.17 per share for April, May and June 2026.
Declaration date for all three payments was March 18, 2026; record dates are April 15, May 15 and June 11, 2026, with payment dates April 30, May 29 and June 30, 2026. The company said it targets distributing roughly 90%–100% of taxable quarterly income to maintain RIC tax treatment.
Capital Southwest (Nasdaq: CSWC) and Trinity Capital (Nasdaq: TRIN) formed a 50/50 joint venture on March 16, 2026 to invest primarily in first-out senior secured debt in the lower middle market. Each partner committed $50 million, creating initial equity of $100 million, and the JV plans to use a senior-secured credit facility to obtain leverage for portfolio investments.
The JV's board of managers will have equal representation from both firms, and investment and operational decisions will be overseen jointly.
Trinity Capital (Nasdaq: TRIN) committed $35 million in growth capital to Monteris Medical to support commercialization of the NeuroBlate System and expansion of clinical research programs. The NeuroBlate System is an MRI-guided, robotically controlled laser interstitial thermal therapy platform for brain tumors, radiation necrosis, and drug-resistant epilepsy.
The financing complements Monteris' Series E equity support and is intended to accelerate commercial expansion, product innovation, and clinical adoption at neuroscience centers.
Emboline closed $20 million in growth capital from Trinity Capital (Nasdaq: TRIN) to fund commercialization of the Emboliner® Embolic Protection System and further platform development. The company completed enrollment in its IDE trial (NCT05684146) and will present results on March 29, 2026 at ACC.
Financing will support U.S. and European commercial launch preparations and ongoing regulatory submissions; the Emboliner device remains investigational and is not available for commercial sale.
Trinity Capital (Nasdaq: TRIN) committed $20 million in growth capital to Emboline to support commercial preparation for the Emboliner embolic protection catheter. The Emboliner uses a flexible mesh to capture and remove debris during minimally invasive heart procedures.
Emboline completed patient enrollment in the PROTECT H2H IDE clinical trial; funds will scale manufacturing, expand the team, and support clinical and regulatory milestones ahead of commercial launch.